Quick Answer
CNBX Pharmaceuticals Inc. reported Total Revenue of $0.00 for fiscal year 2025.
CNBX Pharmaceuticals Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $130.1K | -68.3% |
| 2023 | $410.2K | +1269.1% |
| 2022 | $30.0K | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $7.2K | -27.3% |
| 2019 | $9.8K | +2.5% |
| 2018 | $9.6K | +68.9% |
| 2017 | $5.7K | -94.9% |
| 2016 | $112.5K | — |
| 2015 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | $0.00 | — | — |
| May 31, 2025 | $0.00 | — | — |
| February 28, 2025 | $0.00 | -100.0% | — |
| November 30, 2024 | $0.00 | -100.0% | — |
| May 31, 2024 | $0.00 | -100.0% | -100.0% |
| February 29, 2024 | $40.6K | — | -54.6% |
| November 30, 2023 | $89.4K | — | -71.2% |
| May 31, 2023 | $310.2K | — | — |
- CNBX Pharmaceuticals Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from CNBX Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: